ArticleJCO precision oncology2018

Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With

Vivek Subbiah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.